Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) have been given an average rating of “Hold” by the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $3.67.

A number of equities analysts have commented on the stock. StockNews.com started coverage on shares of Lexicon Pharmaceuticals in a research report on Saturday. They issued a “sell” rating on the stock. Piper Sandler reduced their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners reissued a “market perform” rating and issued a $1.00 price objective (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Friday, March 28th.

Lexicon Pharmaceuticals Price Performance

Lexicon Pharmaceuticals stock opened at $0.42 on Tuesday. The business has a 50 day simple moving average of $0.57 and a 200 day simple moving average of $0.96. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.45 and a quick ratio of 7.43. The company has a market capitalization of $103.15 million, a PE ratio of -0.56 and a beta of 1.04. Lexicon Pharmaceuticals has a one year low of $0.28 and a one year high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $26.55 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, sell-side analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Bayesian Capital Management LP acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $31,000. RPO LLC bought a new position in Lexicon Pharmaceuticals in the fourth quarter valued at about $33,000. Renaissance Technologies LLC acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter worth about $38,000. Arizona State Retirement System raised its holdings in Lexicon Pharmaceuticals by 34.4% during the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 16,136 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its position in Lexicon Pharmaceuticals by 60.3% during the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 24,615 shares during the period. Institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.